STOCK TITAN

INNOVEREN SCIENTIFIC INC - $IVRN STOCK NEWS

Welcome to our dedicated page for INNOVEREN SCIENTIFIC news (Ticker: $IVRN), a resource for investors and traders seeking the latest updates and insights on INNOVEREN SCIENTIFIC stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect INNOVEREN SCIENTIFIC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of INNOVEREN SCIENTIFIC's position in the market.

Rhea-AI Summary
Innoveren Scientific Inc. submits its first commercial product, SkinDiscTM Lite, for FDA approval, utilizing autologous platelet-rich plasma for wound healing. The company aims to advance its regenerative medicine-based pipeline with future submissions, including SkinDiscTM Ultra and BreatheEasy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
110.61%
Tags
none
-
Rhea-AI Summary
Innoveren Scientific Inc. completes divestiture of a medical device used in spinal surgeries, generating approximately $869,000 in net proceeds. The purchase price includes a three percent royalty stream on product commercialization. The capital infusion will be used for corporate rebranding, accelerating the acquisition pipeline, and attracting additional investment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
59.83%
Tags
none
INNOVEREN SCIENTIFIC INC

OTC:IVRN

IVRN Rankings

IVRN Stock Data

25.30k
539.41k
109.72%
1.4%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
Tampa

About IVRN

h-cyte, inc., a medical biosciences company, develops and implements various treatment options in regenerative medicine to treat chronic lung diseases. it engages in the development of l-cyte-01 for the treatment of chronic obstructive pulmonary diseases. the company is headquartered in tampa, florida.